about
sameAs
P1889
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsUroplakin gene expression by normal and neoplastic human urotheliumImpact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissueAn Association of Cancer Physicians' strategy for improving services and outcomes for cancer patientsA systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analysesGenome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3Automated collection of quality-of-life data: a comparison of paper and computer touch-screen questionnaires.A Rac/Cdc42 exchange factor complex promotes formation of lateral filopodia and blood vessel lumen morphogenesisProteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility.Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations.Human uroplakin lb gene structure and promoter analysis.Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor.Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect.Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry.Proteomic profiling using mass spectrometry--does normalising by total ion current potentially mask some biological differences?Integrated multi-level quality control for proteomic profiling studies using mass spectrometry.Using the protein chip interface with quadrupole time-of-flight mass spectrometry to directly identify peaks in SELDI profiles--initial evaluation using low molecular weight serum peaks.Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using western blotting.Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyAssociation of serum amyloid A protein and peptide fragments with prognosis in renal cancer.Cancer in old age--is it inadequately investigated and treated?Communication about sexual problems and sexual concerns in ovarian cancer: a qualitative study.Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigationsPersonalized cancer medicine: are we there yet?Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells.Urothelial tissue regulation. Unraveling the role of the stroma.Genome-wide association study identifies multiple risk loci for renal cell carcinoma.Delivery of non-surgical oncology care.Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsA pilot study to investigate the potential of mass spectrometry profiling in the discovery of novel serum markers in chronic renal disease.Proteomics: new perspectives, new biomedical opportunities.Uroplakin gene expression in normal human tissues and locally advanced bladder cancer.High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent.Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein.
P50
Q24596171-C0CF46F0-3602-4DA8-8B33-27E2CC44B5A1Q24612603-6C2C8B8E-53DF-468E-A1A5-0C0C21949A8FQ24617027-C3FD5804-535F-4CE1-868C-FBAA17E887FFQ24671752-266E4A82-87BB-437C-954C-88EFCB54D952Q26851269-A483C3F7-1A4A-44A2-91F3-2BB17C475C17Q28603931-8312D418-4F85-4B54-A781-0109013B6FE9Q28732696-9D24546A-71DB-4919-A47D-AE1B74F2DD3FQ28943264-9604B5A3-451C-4B35-B253-216EB5CEBFF6Q30559421-AE1C4483-4B4D-4CCE-B7FE-1A2538EA9A3EQ30658198-25C88346-20F0-4F51-859F-2DB21AF06492Q30745340-4CD74ECF-54A3-43C9-8FA4-80F8559D070BQ31042241-10559980-B6B6-4960-A829-3A947EECAD90Q31062600-7DF00E9A-93ED-4F86-9868-0789073F1F4FQ31150349-8847D700-A7DA-41B1-BB55-2232431118F7Q33188191-CAA89FF4-CC24-40C3-913A-05BF6C430517Q33218408-6A3DE920-DF09-44B2-BAD9-46F57011C3CCQ33311516-18FFD503-4A61-4E3E-94C9-61FA442A0820Q33389590-056F2738-2967-4FF1-84B3-21E6D2F2C027Q33399808-C5071F67-4550-424E-8AAF-C87397EA82FAQ33401334-1DC51A5E-83CE-431C-BF4D-6EC8C97EDD44Q33489402-7F212ADD-814E-484D-9EE8-B5710B690844Q33551626-6051DB50-E55B-4D21-B749-0BF68D32F83BQ33597715-82D5893B-57D7-4C00-8839-91176EA3014AQ33699714-9A73D1E4-A37C-4FF1-AD28-0320F197EDEBQ33729512-D7AF3281-EEAE-49E7-9CCB-25752B47A541Q33758692-0EFC5CA9-28CB-4280-A269-C22236C79D5CQ33777401-55252AA0-30B3-4F41-BD94-3357372E8BD7Q33793700-EBFE5AAA-BDD6-4BF2-A8AD-55EBB9B8A33AQ33795151-28BBC599-967B-4DCB-ACE7-C3CBC2BA535CQ33804470-43745D15-A98E-4CAC-BFF3-1D39F8AE2EA8Q33808952-D4E24566-3E3A-424A-B49E-F0A50547157EQ33815701-89BEB5B6-7718-4949-A4B4-DCB30E4939DFQ33936327-157069D5-3D43-4CB9-87D2-D172B7FCF805Q33990550-5FFF76D5-2DAA-4AA6-8E62-D04A8016DDDFQ34092071-841A28C6-FE05-442C-99AE-09F7D5470808Q34163600-E653B10A-9538-433B-A012-7F5264CB70BFQ34195428-7A1DBA98-14E5-4AB4-B434-0054BFCF43D8Q34198856-87BD2A8D-EBDF-42DF-A3E5-CF89076DFF86Q34292398-BF451C4C-F6E1-4064-B836-79CA8AEC794AQ34363552-F8DAD063-F129-4FBB-8596-7DD99D853FE6
P50
subject
description
Professor of Cancer Medicine
@en
Professor of Cancer Medicine
@en-gb
name
Peter Selby
@af
Peter Selby
@an
Peter Selby
@ast
Peter Selby
@ay
Peter Selby
@az
Peter Selby
@br
Peter Selby
@ca
Peter Selby
@ce
Peter Selby
@ceb
Peter Selby
@co
type
label
Peter Selby
@af
Peter Selby
@an
Peter Selby
@ast
Peter Selby
@ay
Peter Selby
@az
Peter Selby
@br
Peter Selby
@ca
Peter Selby
@ce
Peter Selby
@ceb
Peter Selby
@co
altLabel
Peter J Selby
@en-gb
Peter John Selby
@af
Peter John Selby
@an
Peter John Selby
@ast
Peter John Selby
@ay
Peter John Selby
@az
Peter John Selby
@br
Peter John Selby
@ca
Peter John Selby
@ce
Peter John Selby
@ceb
prefLabel
Peter Selby
@af
Peter Selby
@an
Peter Selby
@ast
Peter Selby
@ay
Peter Selby
@az
Peter Selby
@br
Peter Selby
@ca
Peter Selby
@ce
Peter Selby
@ceb
Peter Selby
@co
P973
P1006
P1015
P214
P244
P268
P269
P1006
P1015
P106
P1153
35464346500
P1207
n2005024234